SPRB · Spruce Biosciences, Inc.
$52.96
+0.12 (+0.22%)
At close · Aug 19
Market Cap
$152.61M
Shares
2.87M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$52.96
Open$54.18
Day$52.02–54.93
52W close$7.00–182.60
Avg vol 30d56K
Short int429K · 14.9% float · 7.6d
Short vol63%
Last earningsNov 12, 2024
DataAug 2025–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Aug 7, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
+9%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
26%
mid-range
Momentum
relative strength
1-month return
+19%
trailing
6-month return
−10%
trailing
YTD return
−39%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $48 › 200d $67 — 200d above 50d
Institutional flow
Accumulating
+97% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.93% of float · ▲ +3.2% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+47%
Y/Y
Free cash flow
$-33.3M
Balance sheet
$48.9M
net cash
Quant / Vol
risk profile
Volatility
1386%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $48 › 200d $67 — 200d above 50d
Institutional flow
Accumulating
+97% holders QoQ · +35 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.93% of float · ▲ +3.2% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $53 · 26%
Range high $183
vs 200-day avg -21%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRB
this stock
Spruce Biosciences, Inc.
|
$152.61M | -39.2% | -100.0% | — | 14.9% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Aug 7, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRB | +12.5% | +18.7% | -9.6% | +23.7% | -39.2% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +13.0% | +15.8% | -21.1% | +20.7% | -52.0% |
Key facts
CIK
1683553
CUSIP
85209E208
13F (30d)
69 filings
65 filers
Visit website
Investor relations